Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Transphagocytic T cells as anti cancer immunotherapyCSIC´s research group, in collaboration with scientists from the Centre of Molecular Biology “Severo Ochoa” (CBMSO-CSIC), the Autónoma University of Madrid and the Health Research Institute of the “La Princesa” University Hospital, developed a new method for anti-cancer immunotherapy based on transphagocytic lymphocytes (tiCD4+ T cells) Companies interested in a patent license or investors for creation of a start-up are being sought. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
New treatment for epidermolysis bullosa and fibrosisCSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Control of neurodegenerative diseases with benzothiazole-benzamide derivativesCSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Kits for cell culture based on hydrogel coatingsCSIC and Complutense University of Madrid have developed new kits for cell culture based on cytocompatible hydrogels coated onto stiff substrates. Due to the excellent adhesion of the hydrogel to these substrates is possible to have mechanically robust platforms, easy to handle as required in a cellular biology laboratory. These new kits have been successfully tested showing an excellent cellular proliferation on the surface of the hydrogel. Besides, this technology allows the detachment of a cell monolayer without the need of chemical or biological agents preserving the viability of cell harvesting. Industrial partners from the biotechnology with expertise in cell culture are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Peptide for cancer control linked to IL13RCSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Piperidine derivatives for the control of Parkinson's and Alzheimer'sCSIC has synthesized a series of piperidine derivatives that are capable of inhibiting the activity of the enzyme phosphodiesterase-8 (PDE8). This inhibitory activity makes them useful for the treatment of neurodegenerative diseases in which this enzyme is overexpressed. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, and Parkinson, among others. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Regulatory compounds of synaptic transmission for the treatment of neurological diseasesThe CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Antibiotics to treat diseases caused by HelicobacterCSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Effective method for plant wound healingCSIC and the Center for Research in Agricultural Genomics have developed an effective method for plant tissue regeneration that involves the use of a bacterial cellulose-based biopolymer. The application of this material directly in plant wounds enhances the formation of new cells layers which boosts the healing processes. Industrial partners are being sought to exploit the existing know-how through a patent license agreement. An offer for Patent Licensing
Ivan Rodriguez RoselloUniversidad de AlicanteIvan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante
IDIBELL posted this:
Drug repurposing for lupus nephritis therapyDrug repurposing for lupus nephritis therapy. Compound X, already approved for human use in other medical indications, administered orally, can be repurposed for lupus nephritis treatment. The principal goal of compound X therapy in lupus nephritis is to normalize renal function or, at least, to prevent the progressive loss of renal function. ✓ Less side effects than the standard of care ✓ Already approved for human in other medical indications (Reprofiling) ✓ Market with 1 approval in last 50 years
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Biocompatible self-generating cell stimulatorCSIC through the Instituto de Microelectrónica de Barcelona - Centro Nacional de Microelectrónica, has developed a device based on nanogenerators for electrical cells stimulation without the need of electrodes or bulky devices. The device is biocompatible and, among its multiple applications, is able to actuate in medical prostheses as an enhancer of cellular growth and proliferation, which permits an early lesion recovery (such as a fracture or wound). Industrial partners dedicated to the development of medical devices for cells stimulation, in particular, focused onto therapeutic treatments of non-healing wounds, are being sought to collaborate through a patent license agreement.
Consejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones CientíficasConsejo Superior de Investigaciones Científicas posted this:
Molecular Method that radically improves the diagnosis of Hereditary hemorrhagic telangiectasia (HHT)Molecular Method that radically improves the diagnosis of Hereditary hemorrhagic telangiectasia (HHT). The Granada University, Health and Progress Foundation, and the CSIC have developed a diagnostic molecular system for the HHT by getting a simple liquid biopsy from the patient. Industrial partners are being sought to collaborate through a patent license agreement to use this molecular diagnostic system with the possibility of informatics support.
Radoslaw RudzCentre Technology Transfer CITTRURadoslaw Rudz posted this:
Licensing Manager at Centre Technology Transfer CITTRU
